<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568047</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-202</org_study_id>
    <secondary_id>2009-012897-12</secondary_id>
    <nct_id>NCT01568047</nct_id>
  </id_info>
  <brief_title>Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients</brief_title>
  <official_title>Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet®) or Levodopa/Benserazide 100/25 mg (Madopar®/Restex®) and With Motor Fluctuations (&quot;Wearing-off&quot; Phenomenon)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the tolerability and the effect of BIA 9-1067 at
      steady-state on the levodopa pharmacokinetics in Parkinson's Disease (PD) patients treated
      with levodopa/dopa-decarboxylase inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre, double-blind, randomised, placebo-controlled study in four parallel groups of PD
      patients treated with standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or
      levodopa/benserazide 100/25 mg (Madopar®/Restex®) and with motor fluctuations (&quot;wearing-off&quot;
      phenomenon)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Observed Maximum Concentration</measure>
    <time_frame>28 days</time_frame>
    <description>Baseline period - to be switched respectively to standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg (Madopar®/Restex®) and to adjust the number of daily doses.
Test Period - After the baseline period during the 21 to 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time to Observed Maximum Concentration</measure>
    <time_frame>28 days</time_frame>
    <description>Baseline period - to be switched respectively to standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg (Madopar®/Restex®) and to adjust the number of daily doses.
Test Period - After the baseline period during the 21 to 28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-6 - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to to 6 h Postdose (AUC [0-6])</measure>
    <time_frame>28 days</time_frame>
    <description>Baseline period - to be switched respectively to standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg (Madopar®/Restex®) and to adjust the number of daily doses.
Test Period - After the baseline period during the 21 to 28 days</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLC, Placebo
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 - 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg BIA 9-1067 (OPC, Opicapone)
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 - 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg BIA 9-1067 (OPC, Opicapone)
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 - 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg BIA 9-1067 (OPC, Opicapone)
Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once-daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PLC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>BIA 9-1067 - 5 mg single-dose</description>
    <arm_group_label>BIA 9-1067 - 5 mg</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>BIA 9-1067 - 15 mg single-dose</description>
    <arm_group_label>BIA 9-1067 - 15 mg</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>BIA 9-1067 - 30 mg single-dose</description>
    <arm_group_label>BIA 9-1067 - 30 mg</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/Carbidopa</intervention_name>
    <description>Levodopa 100 mg Carbidopa 25 mg</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>BIA 9-1067 - 5 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 - 15 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 - 30 mg</arm_group_label>
    <other_name>Sinemet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/Benzerazide</intervention_name>
    <description>Levodopa 100 mg Benzerazide 25 mg</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>BIA 9-1067 - 5 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 - 15 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 - 30 mg</arm_group_label>
    <other_name>Madopar®/Restex®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        At screening (admission to the baseline period):

          -  Male or female of non-childbearing potential (by reason of surgery or postmenopausal);

          -  Age ≥ 30 years;

          -  A diagnosis of PD according to the UK PDS Brain Bank diagnostic criteria (bradykinesia
             and at least one of the following: muscular rigidity, rest tremor and postural
             instability);

          -  Predictable signs of end-of-dose deterioration despite &quot;optimal&quot; levodopa/carbidopa or
             levodopa/benserazide therapy;

          -  Modified Hoehn and Yahr stage of less than 5 in the &quot;off&quot; state; mean duration of
             &quot;off&quot; state ≥ 1.5 h during waking hours (based on historical information);

          -  Results of clinical laboratory tests acceptable by the investigator (not clinically
             significant for the well-being of the patient or for the purpose of the study);

          -  Able and willing to give written informed consent.

        At randomisation (completion of the baseline period):

          -  Been treated with a stable regimen of 3 to 8 doses per day of standard-release
             levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg
             (Madopar®/Restex®) for at least 1 week prior to randomisation;

          -  Mean duration of &quot;off&quot; state ≥ 1.5 h during waking hours (average of recordings of
             last 3 evaluable days on patient's diary);

          -  Concomitant anti-Parkinsonian medication (other than apomorphine, entacapone or
             tolcapone) in stable doses for at least 4 weeks prior to admission.

        Exclusion Criteria:

        At screening (admission to the baseline period):

          -  Non-idiopathic parkinsonism (atypical parkinsonism, symptomatic parkinsonism,
             Parkinson-plus syndrome);

          -  Treated with entacapone, tolcapone, neuroleptics, antidepressants (except
             serotonin-specific reuptake inhibitors or imipramines [desipramine, imipramine,
             clomipramine and amitriptyline]), monoamine oxidase inhibitors (except selegiline up
             to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or
             rasagiline up to 1 mg/day) or antiemetics (except domperidone) within 2 weeks prior to
             admission;

          -  Treated with any investigational product within 1 month prior to admission (or within
             5 half-lives, whichever is longer);

          -  A psychiatric or any medical condition that might place him/her at increased risk or
             interfere with assessments;

          -  Known hypersensitivity to any of the ingredients of the investigational products;

          -  A history of abuse of alcohol, drugs or medications within the last 2 years;

          -  A clinically relevant ECG abnormality;

          -  A history or current evidence of heart disease, including but not limited to
             myocardial infarction, angina, congestive heart failure and cardiac arrhythmia;

          -  Unstable concomitant disease being treated with changing doses of medication;

          -  A history or current evidence of any relevant disease in the context of this study,
             i.e., with respect to the safety of the patient (e.g., hepatic impairment) or related
             to the study conditions;

          -  A test positive for the HIV-1 or HIV-2 antibodies, or hepatitis B surface antigen
             (HbsAg), or hepatitis C antibody (HCVAb);

          -  Donated blood or received blood or blood products within the 6 months prior to
             admission;

          -  Pregnant, breast-feeding or of childbearing potential;

          -  Other condition or circumstance that, in the opinion of the investigator, may
             compromise the patient's ability to comply with the study protocol.

        At randomisation (completion of the baseline period):

          -  Treated with levodopa/DDCI in a 10:1 ratio or in a controlled-release formulation
             during the baseline period;

          -  Treated with apomorphine during the baseline period;

          -  A clinically relevant ECG abnormality.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neurology C.M.D.T.A. NEOMED</name>
      <address>
        <city>Brasov</city>
        <zip>500 283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology-Quantum Medical Center</name>
      <address>
        <city>Bucharest</city>
        <zip>024 092</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Medicina Fizica si Recuperare Medicala-Spitalul Clinic Judetean de Urgenta Craiova</name>
      <address>
        <city>Craiova</city>
        <zip>200 642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ukrainian State Scientific Research Institute of Medical and Social Problems of Disability, Department of Neurology and Adjustment Conditions</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department No. 23 of Communal setting of medical care Kharkiv's regional clinical psychiatric hospital No. 3,</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neuroinfections and multiple sclerosis, SI &quot;Institute of Neurology, Psychiatry and Narcology of AMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Physiology and Pathology of Extrapyramidal Nervous System SI &quot;Institute of Gerontology, AMS Ukraine&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <results_first_submitted>February 5, 2014</results_first_submitted>
  <results_first_submitted_qc>December 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2015</results_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>BIA 9-1067</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Opicapone</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Benserazide, levodopa drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>PLC, Placebo</description>
        </group>
        <group group_id="P2">
          <title>BIA 9-1067 (5 mg)</title>
          <description>OPC, Opicapone</description>
        </group>
        <group group_id="P3">
          <title>BIA 9-1067 (15 mg)</title>
          <description>OPC, Opicapone</description>
        </group>
        <group group_id="P4">
          <title>BIA 9-1067 (30 mg)</title>
          <description>OPC, Opicapone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>PLC, Placebo</description>
        </group>
        <group group_id="B2">
          <title>BIA 9-1067 (5 mg)</title>
          <description>5 mg BIA 9-1067 - OPC, Opicapone</description>
        </group>
        <group group_id="B3">
          <title>BIA 9-1067 (15 mg)</title>
          <description>15 mg BIA 9-1067 - OPC, Opicapone</description>
        </group>
        <group group_id="B4">
          <title>BIA 9-1067 (30 mg)</title>
          <description>30 mg BIA 9-1067 - OPC, Opicapone</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤ 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 49 and 88 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 88 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Observed Maximum Concentration</title>
        <description>Baseline period - to be switched respectively to standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg (Madopar®/Restex®) and to adjust the number of daily doses.
Test Period - After the baseline period during the 21 to 28 days</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PLC, Placebo</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 5 mg</title>
            <description>5 mg BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 15 mg</title>
            <description>15 mg BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 30 mg</title>
            <description>30 mg BIA 9-1067 - OPC, Opicapone</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Observed Maximum Concentration</title>
          <description>Baseline period - to be switched respectively to standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg (Madopar®/Restex®) and to adjust the number of daily doses.
Test Period - After the baseline period during the 21 to 28 days</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax (levodopa) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1484" spread="26.0"/>
                    <measurement group_id="O2" value="1446" spread="37.6"/>
                    <measurement group_id="O3" value="1753" spread="43.4"/>
                    <measurement group_id="O4" value="1832" spread="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (levodopa) Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1203" spread="29.4"/>
                    <measurement group_id="O2" value="1868" spread="31.8"/>
                    <measurement group_id="O3" value="1806" spread="28.4"/>
                    <measurement group_id="O4" value="2584" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (3-OMD) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4701" spread="46.7"/>
                    <measurement group_id="O2" value="4631" spread="31.6"/>
                    <measurement group_id="O3" value="3529" spread="50.7"/>
                    <measurement group_id="O4" value="6222" spread="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (3-OMD) Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3770" spread="45.0"/>
                    <measurement group_id="O2" value="2633" spread="21.2"/>
                    <measurement group_id="O3" value="1197" spread="71.8"/>
                    <measurement group_id="O4" value="1603" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (BIA 9-067) Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">BIA 9-067 was not administered</measurement>
                    <measurement group_id="O2" value="240" spread="186"/>
                    <measurement group_id="O3" value="233" spread="71.8"/>
                    <measurement group_id="O4" value="480" spread="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-6 - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to to 6 h Postdose (AUC [0-6])</title>
        <description>Baseline period - to be switched respectively to standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg (Madopar®/Restex®) and to adjust the number of daily doses.
Test Period - After the baseline period during the 21 to 28 days</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PLC, Placebo</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 5 mg</title>
            <description>5 mg BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 15 mg</title>
            <description>15 mg BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 30 mg</title>
            <description>30 mg BIA 9-1067 - OPC, Opicapone</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-6 - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to to 6 h Postdose (AUC [0-6])</title>
          <description>Baseline period - to be switched respectively to standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg (Madopar®/Restex®) and to adjust the number of daily doses.
Test Period - After the baseline period during the 21 to 28 days</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-6 (levodopa) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2841" spread="30.6"/>
                    <measurement group_id="O2" value="3451" spread="45.2"/>
                    <measurement group_id="O3" value="2734" spread="50.4"/>
                    <measurement group_id="O4" value="3862" spread="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-6 (levodopa) Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2510" spread="27.7"/>
                    <measurement group_id="O2" value="4041" spread="18.3"/>
                    <measurement group_id="O3" value="4044" spread="38.7"/>
                    <measurement group_id="O4" value="6297" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-6 (3-OMD) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23301" spread="39.7"/>
                    <measurement group_id="O2" value="23934" spread="28.3"/>
                    <measurement group_id="O3" value="18748" spread="58.8"/>
                    <measurement group_id="O4" value="34177" spread="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-6 (3-OMD) Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21228" spread="45.4"/>
                    <measurement group_id="O2" value="14883" spread="22.2"/>
                    <measurement group_id="O3" value="6685" spread="73.1"/>
                    <measurement group_id="O4" value="9059" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-6 (BIA 9-067) Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">BIA 9-067 was not administered</measurement>
                    <measurement group_id="O2" value="627" spread="202"/>
                    <measurement group_id="O3" value="698" spread="73.1"/>
                    <measurement group_id="O4" value="1188" spread="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time to Observed Maximum Concentration</title>
        <description>Baseline period - to be switched respectively to standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg (Madopar®/Restex®) and to adjust the number of daily doses.
Test Period - After the baseline period during the 21 to 28 days</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PLC, Placebo</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 5 mg</title>
            <description>5 mg BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 15 mg</title>
            <description>15 mg BIA 9-1067 - OPC, Opicapone</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 30 mg</title>
            <description>30 mg BIA 9-1067 - OPC, Opicapone</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time to Observed Maximum Concentration</title>
          <description>Baseline period - to be switched respectively to standard-release levodopa/carbidopa 100/25 mg (Sinemet®) or levodopa/benserazide 100/25 mg (Madopar®/Restex®) and to adjust the number of daily doses.
Test Period - After the baseline period during the 21 to 28 days</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax (levodopa) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="1.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.5" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (levodopa) Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.5" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (3-OMD) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.25" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="0.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (3-OMD) Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (BIA 9-067) Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">BIA 9-067 was not administered</measurement>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo, PLC</description>
        </group>
        <group group_id="E2">
          <title>BIA 9-1067 (5 mg)</title>
          <description>5 mg BIA 9-1067, OPC, Opicapone</description>
        </group>
        <group group_id="E3">
          <title>BIA 9-1067 (15 mg)</title>
          <description>15 mg BIA 9-1067, OPC, Opicapone</description>
        </group>
        <group group_id="E4">
          <title>BIA 9-1067 (30 mg)</title>
          <description>30 mg BIA 9-1067, OPC, Opicapone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG EFFECT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PHOSPHOKINASE INCREASED BLOOD LACTATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DEHYDROGENASE INCREASED BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DYSKINESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>BRADYPHRENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>BIAL – Portela &amp; Cª S.A.</organization>
      <phone>+351-229866100</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

